GLP-1 Evidence

Airteagal

Cógais GLP-1 agus Osteoartrítis na Glúine: Torthaí

Moladh caillteanas meáchain do osteoarthritis na glúine riamh, agus bhí sé i gcónaí i ndán d'aicme dhrugaí a tháirgeann 15–20% caillteanas meáchain coirp go hiontaofa go dtástálfaí í ann. Tástáladh triail amháin anois. Seo an méid a fuair sí, agus an méid nár fuair.

Updated 4 min read 40 citations

Laige taobh istigh de sheomra otharchairte unoccupied le leaba, rian ardaithe ceiling agus suíocháin
Official Navy Page from United States of America MC2 Todd… · Public domain · Wikimedia Commons

Cén fáth a bhfuil ciall leis an gceist

Ní caitheamh meicniúil amháin é osteoarthritis na glúine, ach tá ualach meicniúil mar chuid den phictiúr, agus ciallaíonn meáchan coirp níos lú níos lú ualaigh ar alt a iompraíonn meáchan — réasúnaíocht ortaipéideach atá ann le fada seachas toradh ó thrialacha GLP-1. Tá otracht nasctha le osteoarthritis freisin trí chosáin mheitibileacha agus athlastacha a théann níos faide ná ualú simplí — tá fíochán adapóiseach gníomhach go meitibileach, agus is bealach dara sochreidte é athlasadh sistéamach trína bhféadfadh caillteanas meáchain cabhrú le hailt nach n-iompraíonn aon mheáchan ar chor ar bith, mar shampla na lámha. Is iarrthóir réasúnta le tástáil é druga a tháirgeann caillteanas meáchain suntasach agus, de réir athbhreithnithe meicníochtúla ar an aicme, athruithe i rialáil goile agus fuinnimh trí chosáin lárnacha agus imeallacha [37].

An trial

Thástáil triail randamaithe, faoi rialú placebo, semaglutide uair sa tseachtain go sonrach i ndaoine a raibh otracht agus osteoarthritis na glúine orthu [17]. Is daonra difriúil agus pointe deiridh príomhúil difriúil é seo ó thrialacha otrachta semaglutide agus tirzepatide a chlúdaítear in áiteanna eile ar an suíomh seo: ba iad na torthaí a tomhaiseadh anseo ná pian osteoarthritis agus feidhm fhisiciúil, ní meáchan amháin. Thuairiscigh an triail feabhas níos mó i ngrúpa semaglutide ná i ngrúpa an phlaicéabó ar bhearta péine agus feidhme araon, taobh leis an gcaillteanas meáchain a fheictear go comhsheasmhach leis an druga seo i dtrialacha eile. Is cineál toraidh atá nua i ndáiríre é sin don aicme dhrugaí seo — triail randamaithe a bhfuil pointe deiridh sonrach altach aici, ní tátal a bhaintear as trialacha caillteanas meáchain a tharla a fhiafraí faoi phian mar bheart tánaisteach.

Trí chosán, trí leibhéal éagsúla fianaise

CosánAn méid a thacaíonn leisCé chomh daingean is atá sé
Ualach meicniúil níos lú ó chaillteanas meáchainRéasúnaíocht ortaipéideach atá ann le fada do chaillteanas meáchain in OA na glúine i gcoitinneNí toradh sonrach GLP-1 é, agus taobh amuigh de shraith tagartha an tsuímh seo
Fianaise thrialach dhíreach in OA na glúineTriail randamaithe amháin, faoi rialú placebo, sa daonra beacht seo [17]Fíor, ach triail amháin
Caillteanas matáin a thacaíonn le hailt le linn cóireálaSonraí comhdhéanaimh choirp agus maise seasc ó thrialacha GLP-1 i gcoitinne [3] [7]Fíor, agus oibríonn sé sa treo contrártha

Tá tábhacht leis an tríú ró sin agus is éasca é a chailleadh i gclúdach na trialach seo. Tá maise sheasc — lena n-áirítear an matán a chobhsaíonn alt na glúine — thart ar cheathrú go trian den mheáchan a chailltear ar na drugaí seo, toradh a chlúdaíonn an suíomh seo go mion ar a leathanach caillteanas matáin. Bhí toradh glan na trialach osteoarthritis fós dearfach ar phian agus ar fheidhm, rud a chiallaíonn nár shárigh cibé matán a cailleadh tairbhe an laghdaithe ualaigh agus an éifeacht fhéideartha frith-athlastach. Ach ciallaíonn sé gurb é an cur síos macánta ar éifeacht an druga seo ar alt ná "glanmhéid dhá rud atá ag tarraingt i dtreonna difriúla," ní "cabhraíonn caillteanas meáchain le hailt" go simplí.

An méid nach n-insíonn an triail duit

Ní bhunaíonn triail amháin i ndruga amháin, i ndaoine a raibh otracht agus osteoarthritis na glúine diagnóisithe orthu ag am liostála, éifeacht don aicme iomlán, d'ailt eile, do dhaoine gan otracht, nó do thorthaí struchtúracha fadtéarmacha mar thoirt chartaláige. Ní insíonn sé duit ach an oiread cé chomh marthanach agus atá an tairbhe tar éis stad an druga — ceist a fhreagraíonn leathanach an stadta an tsuímh seo go neamhfhabhrach cheana féin don mheáchan féin, agus níl aon sonraí leantóireachta osteoarthritis tiomnaithe ann le rá an leanann faoiseamh péine alt an patrún céanna aisiompaithe.

An méid a chiallaíonn sé seo go praiticiúil

Má tá pian sa ghlúin agus meáchan iomarcach ann le chéile, is píosa fianaise breise anois é seo — ceann sonrach, randamaithe — go bhféadfadh caillteanas meáchain druga GLP-1 aistriú go tairbhe altach intomhaiste, ní uimhir ar mheá amháin. Ní fianaise í go gcóireálann na drugaí seo osteoarthritis neamhspleách ar chaillteanas meáchain, agus ní fianaise í d'ailt eile ná do dhaonraí eile. Tá feidhm anseo freisin ag próifíl na fo-iarsmaí agus ag an gceist caillteanas matáin a bhaineann le gach úsáid den aicme dhrugaí seo; níl ceachtar difriúil toisc gur alt seachas básta an toradh sprice.

Ceisteanna coitianta

An gcóireálann semaglutide osteoarthritis, nó an gcabhraíonn sé trí chaillteanas meáchain amháin?
Ní scarann an triail an dá cheann. Thástáil sí an druga i gcoinne placebo agus thomhais sí pian agus feidhm, agus fuair sí tairbhe; níor thástáil sí an bhfuil an éifeacht ann neamhspleách ar athrú meáchain [17].
An gcailleann an druga matán timpeall na glúine go sonrach?
Tomhaiseann na sonraí comhdhéanaimh choirp foilsithe an mhaise sheasc iomlán, ní matán ag alt sonrach, mar sin ní féidir leo é sin a fhreagairt go beacht — ach léiríonn siad caillteanas suntasach maise seasc san iomlán le linn cóireála [3].
An raibh an triail seo i semaglutide amháin, nó an mbaineann sí le tirzepatide freisin?
Níor tástáladh ach semaglutide sa daonra sonrach seo agus ag an bpointe deiridh seo go dtí seo. Is bunús réasúnta é meánchaillteanas meáchain níos mó tirzepatide (féach an leathanach tirzepatide) le bheith ag súil le héifeacht inchomparáide nó níos mó, ach is eatramhú é sin, ní fianaise thrialach.
Má stopaim an druga, an imíonn an tairbhe altach in éineacht leis an meáchan?
Níl aon sonraí leantóireachta fadtéarmacha tiomnaithe ann faoin gceist sin. I bhfianaise cé chomh comhsheasmhach agus a fhilleann meáchan tar éis stad (féach cad a tharlaíonn nuair a stopann tú), bheadh sé réasúnta a bheith ag súil go leanfadh comharthaí altacha an meáchan, ach níor tomhaiseadh é seo go díreach.
Táblaí cruinne scaoilte le cód aitheantais, feicthe ó thuas
Larry D. Moore · CC BY 4.0 · Wikimedia Commons
An cruthúnas atá taobh thiar den leathanach seo Bar dhíreach a thaispeánann comhoibriú na 40 foilsitheachta a luaitear ar an leathanach seo de réir cineál staidéir. 13215meta-analysis (13)randomised trial (21)review (5)other (1)
40 foils, 2016–2026. Is é sin meascán le trialacha agus sintéis ann, atá mar an suíomh óna bhfuil éileamh faoi chúis réasúnta. Téarma: liosta luaiteanna féin an leathanach seo, thíos.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes Natale P, Green SC, Tunnicliffe DJ, et al. · The Cochrane database of systematic reviews · 2025 · Meta-analysis DOIPubMed 39963952Full text
  2. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement Oprea AD, Ostapenko LJ, Sweitzer B, et al. · British journal of anaesthesia · 2025 · Systematic review DOIPubMed 40379536Full text
  3. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis Karakasis P, Patoulias D, Fragakis N, et al. · Metabolism: clinical and experimental · 2025 · Meta-analysis DOIPubMed 39719170
  4. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  5. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials Chen JY, Hsu TW, Liu JH, et al. · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025 · Meta-analysis DOIPubMed 39863261
  6. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials Apperloo EM, Neuen BL, Fletcher RA, et al. · The lancet. Diabetes & endocrinology · 2024 · Meta-analysis DOIPubMed 38991584
  7. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials Bikou A, Dermiki-Gkana F, Penteris M, et al. · Expert opinion on pharmacotherapy · 2024 · Systematic review DOIPubMed 38629387
  8. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management Hiramoto B, McCarty TR, Lodhia NA, et al. · The American journal of gastroenterology · 2024 · Meta-analysis DOIPubMed 38634551Full text
  9. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Shi Q, Nong K, Vandvik PO, et al. · BMJ (Clinical research ed.) · 2023 · Meta-analysis DOIPubMed 37024129Full text
  10. Weight loss efficiency and safety of tirzepatide: A Systematic review Lin F, Yu B, Ling B, et al. · PloS one · 2023 · Meta-analysis DOIPubMed 37141329Full text
  11. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease Zhang Y, Jiang L, Wang J, et al. · Cardiovascular diabetology · 2022 · Meta-analysis DOIPubMed 36335326Full text
  12. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis Tan HC, Dampil OA, Marquez MM · Journal of the ASEAN Federation of Endocrine Societies · 2022 · Meta-analysis DOIPubMed 36578889Full text
  13. Anti-diabetic drugs and weight loss in patients with type 2 diabetes Lazzaroni E, Ben Nasr M, Loretelli C, et al. · Pharmacological research · 2021 · Systematic review DOIPubMed 34302978
  14. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  15. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  16. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study Harrison SA, Frias JP, Lucas KJ, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · Randomised controlled trial DOIPubMed 38447814
  17. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40960239
  18. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight Look M, Dunn JP, Kushner RF, et al. · Diabetes, obesity & metabolism · 2025 · Randomised controlled trial DOIPubMed 39996356Full text
  19. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Ryan DH, Lingvay I, Deanfield J, et al. · Nature medicine · 2024 · Randomised controlled trial DOIPubMed 38740993Full text
  20. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis Bliddal H, Bays H, Czernichow S, et al. · The New England journal of medicine · 2024 · Randomised controlled trial DOIPubMed 39476339
  21. Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog Guo W, Xu Z, Zou H, et al. · Molecular metabolism · 2023 · Randomised controlled trial DOIPubMed 37364710Full text
  22. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37952131
  23. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes Silver HJ, Olson D, Mayfield D, et al. · Diabetes, obesity & metabolism · 2023 · Randomised controlled trial DOIPubMed 37188932Full text
  24. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes Heise T, DeVries JH, Urva S, et al. · Diabetes care · 2023 · Randomised controlled trial DOIPubMed 36857477Full text
  25. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Kadowaki T, Isendahl J, Khalid U, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35131037
  26. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Gastaldelli A, Cusi K, Fernández Landó L, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468325
  27. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial Heerspink HJL, Sattar N, Pavo I, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 36152639
  28. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Garvey WT, Batterham RL, Bhatta M, et al. · Nature medicine · 2022 · Randomised controlled trial DOIPubMed 36216945Full text
  29. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Wilding JPH, Batterham RL, Davies M, et al. · Diabetes, obesity & metabolism · 2022 · Randomised controlled trial DOIPubMed 35441470Full text
  30. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial Klausen MK, Jensen ME, Møller M, et al. · JCI insight · 2022 · Randomised controlled trial DOIPubMed 36066977Full text
  31. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial Rubino D, Abrahamsson N, Davies M, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33755728Full text
  32. Once-Weekly Semaglutide in Adults with Overweight or Obesity Wilding JPH, Batterham RL, Calanna S, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 33567185
  33. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes Gerstein HC, Sattar N, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34215025
  34. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity Friedrichsen M, Breitschaft A, Tadayon S, et al. · Diabetes, obesity & metabolism · 2021 · Randomised controlled trial DOIPubMed 33269530Full text
  35. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Coskun T, Sloop KW, Loghin C, et al. · Molecular metabolism · 2018 · Randomised controlled trial DOIPubMed 30473097Full text
  36. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Blundell J, Finlayson G, Axelsen M, et al. · Diabetes, obesity & metabolism · 2017 · Randomised controlled trial DOIPubMed 28266779Full text
  37. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Marso SP, Bain SC, Consoli A, et al. · The New England journal of medicine · 2016 · Randomised controlled trial DOIPubMed 27633186
  38. GLP-1 Receptor Agonists Rosen CJ, Ingelfinger JR · The New England journal of medicine · 2026 · Review DOIPubMed 41931049
  39. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance Bansal MB, Patton H, Morgan TR, et al. · Hepatology (Baltimore, Md.) · 2026 · Review DOIPubMed 41201884
  40. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation Moiz A, Filion KB, Tsoukas MA, et al. · The American journal of medicine · 2025 · Review DOIPubMed 39892489

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original